S&P ASX All Technology

3,109.60

1.94%

Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.

Get Started

MNOV

Medicinova (MNOV)

Medicinova Inc

Date:

Regulatory News

Text Search:

Sort by:

Non-Regulatory News

Showing the most relevant articles for your search:NASDAQ:MNOV

1 2 3 4 5 6 7 8 9 10 Next >>

Date	Time	Source	Headline	Symbol	Company
14/05/2024	20:00	GlobeNewswire Inc.	MediciNova Receives Notice of Allowance for New Patent Covering MN-166 (ibudilast) for the Treatment of Chlorine-Induced Acute Respiratory Distress Syndrome	NASDAQ:MNOV	Medicinova Inc
10/05/2024	06:15	Edgar (US Regulatory)	Form 10-Q - Quarterly report [Sections 13 or 15(d)]	NASDAQ:MNOV	Medicinova Inc
07/05/2024	20:00	GlobeNewswire Inc.	MediciNova Receives Issue Notification for New Patent Covering Extended-Release Formulations of MN-166 (ibudilast)	NASDAQ:MNOV	Medicinova Inc
03/04/2024	10:00	GlobeNewswire Inc.	MediciNova Announces Abstract Regarding Results of a Clinical Trial of MN-166 (ibudilast) in Glioblastoma Accepted for Presentation at the 2024 American Society of Clinical Oncology Annual Meeting (2024 ASCO)	NASDAQ:MNOV	Medicinova Inc
27/03/2024	10:00	GlobeNewswire Inc.	MediciNova Receives a Notice of Allowance for a New Patent Covering MN-166 (ibudilast) for the Treatment of Macular Injury in Japan	NASDAQ:MNOV	Medicinova Inc
21/03/2024	10:00	GlobeNewswire Inc.	MediciNova Announces Two Abstracts regarding MN-001 (tipelukast) and MN-002 Accepted for Presentation at the 92nd EAS 2024 Congress, the Annual Meeting of the European Atherosclerosis Society	NASDAQ:MNOV	Medicinova Inc
12/03/2024	21:30	GlobeNewswire Inc.	MediciNova Announces New Data and Results of MN-166 (ibudilast) in Chlorine Gas-induced Acute Lung Injury Presented at the 63rd Annual Meeting of the Society of Toxicology	NASDAQ:MNOV	Medicinova Inc
16/02/2024	08:25	Edgar (US Regulatory)	Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]	NASDAQ:MNOV	Medicinova Inc
20/01/2024	08:27	Edgar (US Regulatory)	Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments	NASDAQ:MNOV	Medicinova Inc
20/01/2024	08:25	Edgar (US Regulatory)	Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments	NASDAQ:MNOV	Medicinova Inc
20/01/2024	08:23	Edgar (US Regulatory)	Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments	NASDAQ:MNOV	Medicinova Inc
20/01/2024	08:21	Edgar (US Regulatory)	Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments	NASDAQ:MNOV	Medicinova Inc
17/01/2024	22:00	GlobeNewswire Inc.	MediciNova Receives a Notice of Grant for a New Patent Covering MN-166 (ibudilast) for the Treatment of Macular Injury in China	NASDAQ:MNOV	Medicinova Inc
12/01/2024	08:52	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:MNOV	Medicinova Inc
12/01/2024	08:52	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:MNOV	Medicinova Inc
12/01/2024	08:51	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:MNOV	Medicinova Inc
22/12/2023	10:00	GlobeNewswire Inc.	MediciNova Announces Abstract Regarding MN-166 (ibudilast) in Chlorine Gas-induced Lung Injury Accepted for Presentation at the 63rd Annual Meeting of the Society of Toxicology	NASDAQ:MNOV	Medicinova Inc
07/12/2023	10:00	GlobeNewswire Inc.	MediciNova Receives a Notice of Decision to Grant for a New Patent Covering MN-166 (ibudilast) for the Treatment of Progressive MS in Europe	NASDAQ:MNOV	Medicinova Inc
20/11/2023	23:42	IH Market News	Stocks Set to Open Higher as Investors Await FOMC Minutes and Nvidia Earnings	NASDAQ:MNOV	Medicinova Inc
20/11/2023	10:00	GlobeNewswire Inc.	MediciNova Announces New Data and Results of a Phase 2 Clinical Trial of MN-166 (ibudilast) in Glioblastoma Presented at the 28th Annual Meeting of the Society for Neuro-Oncology	NASDAQ:MNOV	Medicinova Inc
10/11/2023	08:15	Edgar (US Regulatory)	Form 10-Q - Quarterly report [Sections 13 or 15(d)]	NASDAQ:MNOV	Medicinova Inc
27/10/2023	16:00	GlobeNewswire Inc.	MediciNova’s Collaborator Initiates Clinical Development of a Gene Therapy Product for the Treatment of Phenylketonuria	NASDAQ:MNOV	Medicinova Inc
11/10/2023	10:00	GlobeNewswire Inc.	MediciNova Receives a Notice of Allowance for a New Patent Covering the Combination of MN-166 (ibudilast) and Riluzole for the Treatment of Amyotrophic Lateral Sclerosis (ALS) in Canada	NASDAQ:MNOV	Medicinova Inc
05/10/2023	10:00	GlobeNewswire Inc.	MediciNova Receives Gene Therapy Milestone Payment	NASDAQ:MNOV	Medicinova Inc
28/09/2023	09:00	GlobeNewswire Inc.	MediciNova Announces Results of Studies under BARDA Contract to Develop MN 166 (ibudilast) as a Medical Countermeasure Against Chlorine Gas-induced Lung Injury	NASDAQ:MNOV	Medicinova Inc
18/08/2023	09:00	GlobeNewswire Inc.	MediciNova Announces Abstract Regarding MN-166 (ibudilast) in Glioblastoma Accepted for Presentation at the Annual Meeting of the Society for Neuro-Oncology	NASDAQ:MNOV	Medicinova Inc
17/08/2023	09:00	GlobeNewswire Inc.	MediciNova Receives a Notice of Intention to Grant for a New Patent Covering MN-166 (ibudilast) for the Treatment of Macular Injury in Europe	NASDAQ:MNOV	Medicinova Inc
16/08/2023	09:00	GlobeNewswire Inc.	MediciNova Receives a New Patent Covering MN-001 for the Treatment of Scleroderma and Systemic Sclerosis in Europe	NASDAQ:MNOV	Medicinova Inc
15/08/2023	09:00	GlobeNewswire Inc.	MediciNova Receives a Notice of Intention to Grant for a New Patent Covering MN-001 and MN-002 for the Treatment of Advanced NASH in Europe	NASDAQ:MNOV	Medicinova Inc
10/08/2023	06:17	Edgar (US Regulatory)	Form 10-Q - Quarterly report [Sections 13 or 15(d)]	NASDAQ:MNOV	Medicinova Inc